RayKnowChina Research Map
Shortlist

ShanghaiShanghai Jiao Tong University School of Medicine

Xinhua Hospital

上海交通大学医学院附属新华医院

Listed for 30 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Xinhua Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatocellular carcinoma肝细胞癌21 papers led
  2. Stomach cancer胃癌24 papers led
  3. Hepatoblastoma肝母细胞瘤1 paper led
  4. Retinoblastoma视网膜母细胞瘤5 papers led
  5. Osteosarcoma骨肉瘤4 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  7. Neuroblastoma神经母细胞瘤17 papers led
  8. Ewing sarcoma尤文肉瘤0 papers led
  9. Multiple myeloma多发性骨髓瘤2 papers led
  10. Myasthenia gravis重症肌无力2 papers led
  11. Wilson disease肝豆状核变性(Wilson 病)2 papers led
  12. Biliary atresia胆道闭锁9 papers led
  13. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
  14. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
  15. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  16. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  17. Fabry disease法布雷病1 paper led
  18. Pompe disease庞贝病0 papers led
  19. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  20. Behçet disease白塞病0 papers led
  21. Alport syndromeAlport 综合征0 papers led1 open trial led
  22. IgA nephropathyIgA 肾病2 papers led
  23. Gaucher disease戈谢病2 papers led1 open trial led
  24. Niemann–Pick disease type C尼曼-匹克病 C 型1 paper led
  25. Osteogenesis imperfecta成骨不全症0 papers led
  26. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  27. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
  28. Congenital diaphragmatic hernia先天性膈疝3 papers led
  29. Hirschsprung disease先天性巨结肠6 papers led
  30. Inherited epidermolysis bullosa遗传性大疱性表皮松解症4 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Chordoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 21 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
21
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 2220222023: 6620232024: 5520242025: 332025

15 hospitals in Shanghai for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging, AI & early detectionRecurrence & prognosisHepatitis B & cirrhosis
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyRadiology / nuclear medicineGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led21
  1. HNF4A functions as a hepatocellular carcinoma oncogene or tumor suppressor depending upon the AMPK pathway activity status.2025Cancer letters
  2. Arsenic sulfide enhances the therapeutic effect of hepatocellular carcinoma immunotherapy through STAT3-THBS1/CD47 pathway.2025Frontiers in immunologyFree full text
  3. LI-RADS CEUS Nonradiation TRA Version 2024: Application on HCC Patients Treated With Ablation Treatment.2025Ultrasound in medicine & biology
  4. Nomogram for Predicting Microvascular Invasion in Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced MRI and Intravoxel Incoherent Motion Imaging.2024Academic radiology
  5. Comprehensive characterization of β-alanine metabolism-related genes in HCC identified a novel prognostic signature related to clinical outcomes.2024AgingFree full text
  6. Targeting caspase-8: a new strategy for combating hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  7. Ferroptosis and hepatocellular carcinoma: the emerging role of lncRNAs.2024Frontiers in immunology
  8. Lipid metabolism-related long noncoding RNAs: A potential prognostic biomarker for hepatocellular carcinoma.2024World journal of gastroenterologyFree full text
  9. HBV-infected hepatocellular carcinoma can be robustly classified into three clinically relevant subgroups by a novel analytical protocol.2023Briefings in bioinformatics
  10. Arsenic Sulfide Inhibits Hepatocellular Carcinoma Metastasis by Suppressing the HIF-1α/VEGF Pathway.2023Frontiers in bioscience (Landmark edition)
  11. Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network.2023Genome medicineFree full text
  12. Liver transplantation for advanced-stage primary hepatic yolk sac tumor: A case report and literature review.2023MedicineFree full text
  13. Applications of Dynamic Contrast-Enhanced Ultrasound in Differential Diagnosis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in Non-cirrhotic Liver.2023Ultrasound in medicine & biology
  14. A Bayesian Network Prediction Model for Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma: A Multi-institutional Study.2023World journal of surgery
  15. LncRNA MORT Overexpression Inhibits Cancer Cell Migration and Invasion in Hepatocellular Carcinoma by Downregulating NOTCH1.2022Cancer biotherapy & radiopharmaceuticals
  16. Identify an innovative ferroptosis-related gene in hepatocellular carcinoma.2022Journal of clinical laboratory analysisFree full text
  17. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.2021Cancer biomarkers : section A of Disease markersFree full text
  18. Identification of 5 Hub Genes Related to the Early Diagnosis, Tumour Stage, and Poor Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma by Bioinformatics Analysis.2021Computational and mathematical methods in medicineFree full text
  19. CDC20 regulates the cell proliferation and radiosensitivity of P53 mutant HCC cells through the Bcl-2/Bax pathway.2021International journal of biological sciencesFree full text
  20. Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data.2021Journal of hematology & oncologyFree full text
  21. Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion.2021World journal of gastroenterologyFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With HBV-related HCC After Liver TransplantationCompletedNCT04415567Lead (inferred)Start 2018-06
  2. Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular CarcinomaCompletedNCT04401800Study sitePhase 2Start 2020-09
  3. Efficacy Study of TACE to Treat Hepatocellular Carcinoma After OperationStatus unknownNCT02631499Study sitePhase 4Start 2015-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 24 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
24
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 5520222023: 1120232024: 7720242025: 662025

18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06081647

    Age 18 years to 60 years (registered criteria)

    Led by Renji Hospital; 7 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Nanjing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImaging & AINutrition & recovery
Departments in papersPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led24
  1. FKH domain-mediated nuclear FOXP3 suppresses gastric cancer malignancy via c-MYC/CDKN1A regulation, EMT inhibition, and PI3K/AKT signaling modulation.2026Molecular and cellular biochemistry
  2. Non-invasive Assessment of Human Epidermal Growth Factor Receptor 2 Expression in Gastric Cancer Based on Deep Learning: A Computed Tomography-based Multicenter Study.2025Academic radiology
  3. Rational Design and Synthesis of Peptide-Based Probes for Fibroblast Activation Protein-Targeted Magnetic Resonance and NIR-I/II Fluorescence Imaging of Cancer-Associated Fibroblasts.2025Analytical chemistry
  4. BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19-YBX1 Axis to Induce Immune Evasion in Gastric Cancer.2025Cancer immunology researchFree full text
  5. Identification and Validation of Four Serum Biomarkers With Optimal Diagnostic and Prognostic Potential for Gastric Cancer Based on Machine Learning Algorithms.2025Cancer medicineFree full text
  6. Clofoctol impairs the stemness of gastric cancer and induces TNF-mediated necroptosis by directly binding to RanBP2.2025Cellular and molecular life sciences : CMLSFree full text
  7. CT-based scores for extramural vascular invasion and occult peritoneal metastasis correlate with gastric cancer survival.2025European radiology
  8. Mutational signatures in 175 Chinese gastric cancer patients.2024BMC cancerFree full text
  9. Fibronectin-Targeting Dual-Modal MR/NIRF Imaging Contrast Agents for Diagnosis of Gastric Cancer and Peritoneal Metastasis.2024Bioconjugate chemistry
  10. Notum enhances gastric cancer stem-like cell properties through upregulation of Sox2 by PI3K/AKT signaling pathway.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  11. ALKBH5-mediated m6A modification of circFOXP1 promotes gastric cancer progression by regulating SOX4 expression and sponging miR-338-3p.2024Communications biologyFree full text
  12. Unveiling the gastric microbiota: implications for gastric carcinogenesis, immune responses, and clinical prospects.2024Journal of experimental & clinical cancer research : CRFree full text
  13. LINC00355 promotes gastric carcinogenesis by scaffolding p300 to activate CDC42 transcription and enhancing HNRNPA2B1 to stabilize CDC42 mRNA dependent on m6A.2024Molecular carcinogenesis
  14. Application of immune checkpoint inhibitors and microsatellite instability in gastric cancer.2024World journal of gastroenterologyFree full text
  15. Association between Gastric Cancer and 12 Autoimmune Diseases: A Mendelian Randomization Study.2023GenesFree full text
  16. Initial screening of gastric cancer using oral contrast-enhanced trans-abdominal ultrasonography in rural asymptomatic individuals.2022Cancer epidemiology
  17. Machine Learning-based Correlation Study between Perioperative Immunonutritional Index and Postoperative Anastomotic Leakage in Patients with Gastric Cancer.2022International journal of medical sciencesFree full text
  18. Continuous Jejunal Pouch and Residual Stomach Anastomosis Combined with Jejunal Lateral Anastomosis: An Improved Method of Gastrointestinal Reconstruction following Distal Gastrectomy.2022Journal of investigative surgery : the official journal of the Academy of Surgical Research
  19. Long-term outcomes after different treatments for gastric cancer with synchronous liver metastasis: A PRISMA systematic review and network meta-analysis.2022MedicineFree full text
  20. Cancer-associated fibroblasts subtypes and role in invasion and metastasis of gastric cancer.2022Neoplasma
  21. Translational control of Bcl-2 promotes apoptosis of gastric carcinoma cells.2021BMC cancerFree full text
  22. Gastric cancer-secreted exosomal X26nt increases angiogenesis and vascular permeability by targeting VE-cadherin.2021Cancer scienceFree full text
  23. Decreased expression of ATF3, orchestrated by β-catenin/TCF3, miR-17-5p and HOXA11-AS, promoted gastric cancer progression via increased β-catenin and CEMIP.2021Experimental & molecular medicineFree full text
  24. ESRRA promotes gastric cancer development by regulating the CDC25C/CDK1/CyclinB1 pathway via DSN1.2021International journal of biological sciencesFree full text
Chinese-language papers (not in the count)2
  1. [Surgical problems and considerations in conversion treatment of stage IV gastric cancer].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Multiple primary tumors in children: a clinicopathological analysis of four cases].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status2
  1. Application Value of CTCs Detection for Advanced Gastric Cancer PatientsStatus unknownNCT03156777Lead sponsorStart 2016-01
  2. The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy ProcedureRecruitingNCT06081647Study siteN/AStart 2023-12

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

8 hospitals in Shanghai for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 5 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 1.7%.

Papers led
5
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 0020232024: 0020242025: 112025

11 hospitals in Shanghai for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Papers it led4
  1. Stereotactic Body Radiation Therapy Augmented Checkpoint Inhibitor Immunotherapy Response in Heavily Pretreated Metastatic Osteosarcoma.2026International journal of radiation oncology, biology, physics
  2. Nanoengineered 3D-printing scaffolds prepared by metal-coordination self-assembly for hyperthermia-catalytic osteosarcoma therapy and bone regeneration.2024Journal of colloid and interface science
  3. Changes in the small noncoding RNA transcriptome in osteosarcoma cells.2023Journal of orthopaedic surgery and research
  4. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.2022BMC cancer
Earlier papers (2016–2020)6
  1. The prognostic signature of the somatic mutations in Ewing sarcoma: from a network view.2019Japanese journal of clinical oncology
  2. MiR-144 Inhibits Tumor Growth and Metastasis in Osteosarcoma via Dual-suppressing RhoA/ROCK1 Signaling Pathway.2019Molecular pharmacology
  3. Exploring the molecular mechanisms of osteosarcoma by the integrated analysis of mRNAs and miRNA microarrays.2018International journal of molecular medicine
  4. MicroRNA-18a inhibits cell growth and induces apoptosis in osteosarcoma by targeting MED27.2018International journal of oncology
  5. Ras-Association Domain Family 1 Isoform A (RASSF1A) Gene Polymorphism rs1989839 is Associated with Risk and Metastatic Potential of Osteosarcoma in Young Chinese Individuals: A Multi-Center, Case-Control Study.2016Medical science monitor : international medical journal of experimental and clinical research
  6. [Cryptotanshinone down-regulates the expression of VEGF and inhibits angiogenesis in U2OS osteosarcoma cells].2016Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 17 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 1.5%.

Papers led
17
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 6620222023: 1120232024: 5520242025: 002025

34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsMedical oncologyRadiology / nuclear medicineNeurology

Over half of these papers are lab or animal studies.

Papers it led17
  1. Neuroblastoma with high ASPM reveals pronounced heterogeneity and poor prognosis.2024BMC cancer
  2. Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification.2024British journal of cancer
  3. Analysis of the incidence, characteristics, and risk factors of complications during induction chemotherapy in children with high-risk neuroblastoma.2024European journal of pediatrics
  4. The prognostic role of 18F-FDG PET/CT-based response evaluation in children with stage 4 neuroblastoma.2024European radiology
  5. Clozapine-N-oxide protects dopaminergic neurons against rotenone-induced neurotoxicity by preventing ferritinophagy-mediated ferroptosis.2024Free radical biology & medicine
  6. P300 Interacted With N-Myc and Regulated Its Protein Stability via Altering Its Post-Translational Modifications in Neuroblastoma.2023Molecular & cellular proteomics : MCP
  7. Extracellular matrix stiffness controls VEGF165 secretion and neuroblastoma angiogenesis via the YAP/RUNX2/SRSF1 axis.2022Angiogenesis
  8. PCLAF promotes neuroblastoma G1/S cell cycle progression via the E2F1/PTTG1 axis.2022Cell death & disease
  9. Single-cell profiling of peripheral neuroblastic tumors identifies an aggressive transitional state that bridges an adrenergic-mesenchymal trajectory.2022Cell reports
  10. BCL11A Facilitates Cell Proliferation and Metastasis in Neuroblastoma via Regulating the PI3K/Akt Signaling Pathway.2022Current cancer drug targets
  11. A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma.2022European journal of pediatrics
  12. Exploring the prognosis of neuroblastoma in adolescents and adults: a case series and literature review.2022Neoplasma
  13. MCM6 indicates adverse tumor features and poor outcomes and promotes G1/S cell cycle progression in neuroblastoma.2021BMC cancer
  14. Radiogenomics of neuroblastoma in pediatric patients: CT-based radiomics signature in predicting MYCN amplification.2021European radiology
  15. Anti-tumor effect of Huaier extract against neuroblastoma cells in vitro.2021International journal of medical sciences
  16. XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor.2021Journal of experimental & clinical cancer research : CR
  17. Exportin-T: A Novel Prognostic Predictor and Potential Therapeutic Target for Neuroblastoma.2021Technology in cancer research & treatment
Earlier papers (2016–2020)12
  1. Bufalin exerts antitumor effects in neuroblastoma via the induction of reactive oxygen species‑mediated apoptosis by targeting the electron transport chain.2020International journal of molecular medicine
  2. MYT1 attenuates neuroblastoma cell differentiation by interacting with the LSD1/CoREST complex.2020Oncogene
  3. TRIM proteins in neuroblastoma.2019Bioscience reports
  4. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[18F]FGln PET Imaging.2019Molecular imaging and biology
  5. Scattered Dose to Ovary From Radiotherapy for Neuroblastoma in Female Children.2019Technology in cancer research & treatment
  6. Legumain correlates with neuroblastoma differentiation and can be used in prodrug design.2018Chemical biology & drug design
  7. Prognostic value of metabolic indices and bone marrow uptake pattern on preoperative 18F-FDG PET/CT in pediatric patients with neuroblastoma.2018European journal of nuclear medicine and molecular imaging
  8. The deubiquitinating enzyme UCHL1 is a favorable prognostic marker in neuroblastoma as it promotes neuronal differentiation.2018Journal of experimental & clinical cancer research : CR
  9. Both serum and tissue Galectin-1 levels are associated with adverse clinical features in neuroblastoma.2018Pediatric blood & cancer
  10. Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.2017Journal of experimental & clinical cancer research : CR
  11. Clinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma.2017Oncotarget
  12. Phosphoproteomics reveals ALK promote cell progress via RAS/ JNK pathway in neuroblastoma.2016Oncotarget
All its trials on ClinicalTrials.gov, any status5
  1. Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large ModelsCompletedNCT06822842Lead sponsorStart 2025-01
  2. Risk Model for Metastasis Detection of NeuroblastomaEnrolling by invitationNCT06703944Lead sponsorStart 2024-12
  3. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Lead sponsorPhase 4Start 2016-09
  4. Anti-angiogenetic Therapy With Radiotherapy for Pediatric NeuroblastomaStatus unknownNCT02615106Lead sponsorPhase 2Start 2015-11
  5. Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk NeuroblastomaCompletedNCT05373901Study sitePhase 1Start 2022-06

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

15 hospitals in Shanghai for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. The prognostic signature of the somatic mutations in Ewing sarcoma: from a network view.2019Japanese journal of clinical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

16 hospitals in Shanghai for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDrug combinationsDiagnosis, MRD & risk

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

7 hospitals in Shanghai for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosis
Departments in papersOphthalmology / neuro-ophthalmologyNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 2 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 1.0%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

1 hospital in Shanghai for Wilson disease28 hospitals in China for Wilson disease

No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics (ATP7B)Liver disease & transplantDiagnosis & copper tests
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)
Papers it led2
  1. Mechanisms of copper metabolism and cuproptosis: implications for liver diseases.2025Frontiers in immunologyFree full text
  2. Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients and Mice with Wilson Disease.2025The American journal of pathology
Chinese-language papers (not in the count)5
  1. [Analysis of clinical and genetic characteristics of the severe liver disease phenotype in patients with hepatolenticular degeneration].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Factors influencing the clinical phenotype of hepatolenticular degeneration].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  3. [Pregnancy management in patients with hepatolenticular degeneration].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  4. [An interpretation of the British Association for the Study of the Liver practice guideline for the evaluation and treatment of hepatolenticular degeneration].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  5. [Advances in the treatment of Wilson Disease].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status1
  1. An Exploratory Study to Evaluate the Tolerability and Safety of MWAV201 in Subjects With Wilson DiseaseActive, not recruitingNCT06663878Lead sponsorN/AStart 2024-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Biliary atresia

胆道闭锁

Led 9 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 4.2%.

Papers led
9
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 1120232024: 2220242025: 112025

3 hospitals in Shanghai for biliary atresia28 hospitals in China for biliary atresia

No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesScreening & diagnosisDisease mechanisms
Departments in papersPediatricsGastroenterology / hepatology
Papers it led9
  1. PIgR Autoantibody-abundant Circulating Vesicles Contributes to Biliary Injury in Biliary Atresia.2025Journal of pediatric surgery
  2. Predictive modeling for early detection of biliary atresia in infants with cholestasis: Insights from a machine learning study.2024Computers in biology and medicine
  3. Neurotensin contributes to cholestatic liver disease potentially modulating matrix metalloprotease-7.2024The international journal of biochemistry & cell biology
  4. Contribution of ADD3 and the HLA Genes to Biliary Atresia Risk in Chinese.2023International journal of molecular sciencesFree full text
  5. Metabolic regulation of cholestatic liver injury by D-2-hydroxyglutarate with the modulation of hepatic microenvironment and the mammalian target of rapamycin signaling.2022Cell death & diseaseFree full text
  6. Beta-amyloid Deposition in Biliary Atresia Reduces Liver Regeneration by Inhibiting Energy Metabolism and Mammalian Target of Rapamycin Signaling.2022Clinical and translational gastroenterologyFree full text
  7. Diagnostic values of plasma matrix metalloproteinase-7, interleukin-8, and gamma-glutamyl transferase in biliary atresia.2022European journal of pediatrics
  8. Targeted Metabolomics Reveals Birth Screening Biomarkers for Biliary Atresia in Dried Blood Spots.2022Journal of proteome research
  9. Effects of cytomegalovirus infection on the differential diagnosis between biliary atresia and intrahepatic cholestasis in a Chinese large cohort study.2021Annals of hepatology
All its trials on ClinicalTrials.gov, any status2
  1. Dry Blood Spot Screening Test for Biliary Atresia(DBS-SCReBA)WithdrawnNCT03898765Lead sponsorN/AStart 2019-04
  2. Development and Validation of a Screening Score for the Biliary Atresia in Infantile Cholestasis: A Prospective StudyStatus unknownNCT03842150Lead sponsorStart 2014-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

9 hospitals in Shanghai for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

17 hospitals in Shanghai for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Shanghai for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1Active, not recruitingNCT06191354Study siteN/AStart 2023-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Shanghai for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Shanghai for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

12 hospitals in Shanghai for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

15 hospitals in Shanghai for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Shanghai for Alport syndrome60 hospitals in China for Alport syndrome

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Genotype-Phenotype Correlations in Patients With Alport Syndrome
    Phase
    Not given
    Started
    2021-01
    Registry
    NCT04947813

    Age not stated (registered criteria)

    Led by Xinhua HospitalShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Genotype-Phenotype Correlations in Patients With Alport SyndromeRecruitingNCT04947813Lead sponsorStart 2021-01
  2. Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 VariantsNot yet recruitingNCT05133050Lead sponsorN/AStart 2022-01

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led 2 of the 30 English-language PubMed papers on Gaucher disease with an author in mainland China, 2021–2025: 6.7%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Shanghai for Gaucher disease41 hospitals in China for Gaucher disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease
    Phase
    Early phase 1
    Started
    2023-03
    Registry
    NCT06272149

    Age 0 months to 24 months (registered criteria)

    Led by Xinhua HospitalShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurologyPediatricsRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Niemann–Pick disease type C

尼曼-匹克病 C 型

Led 1 of the 16 English-language PubMed papers on Niemann–Pick disease type C with an author in mainland China, 2021–2025: 6.2%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Shanghai for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C

No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led1
  1. Development and validation of a new genotype-phenotype correlation for Niemann-Pick disease type C1.2024Journal of inherited metabolic disease
Earlier papers (2016–2020)1
  1. [Blood 7-ketocholesterol level, clinical features and gene mutation analysis of 18 children with Niemann-Pick disease type C].2016Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status2
  1. Study of Lithium Carbonate to Treat Niemann-Pick Type C1 DiseaseStatus unknownNCT03201627Lead sponsorEarly phase 1Start 2017-07
  2. Safety and Efficacy of Miglustat in Chinese NPC PatientsCompletedNCT03910621Study sitePhase 4Start 2020-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Shanghai for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

17 hospitals in Shanghai for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

13 hospitals in Shanghai for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Chinese-language papers (not in the count)1
  1. [Genome-wide Mendelian randomization study of the pathogenic role of gut microbiota in benign biliary tract diseases].2024Zhonghua wai ke za zhi [Chinese journal of surgery]

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led 3 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 5.0%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Shanghai for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led3
  1. A Nomogram Model for Prenatal Predicting Survival in Infants with Congenital Diaphragmatic Hernia.2026American journal of perinatology
  2. Development and internal validation of a prediction model to predict survival for congenital diaphragmatic hernia in the early postnatal period.2022The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  3. Predictive value of gestational age at diagnosis for outcomes in prenatally diagnosed congenital diaphragmatic hernia.2021The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
Earlier papers (2016–2020)1
  1. Outcomes of Congenital Diaphragmatic Hernia in One of the Twins.2019American journal of perinatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 6 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 3.7%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 1120242025: 002025

5 hospitals in Shanghai for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsSurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led6
  1. Conversion of intestinal smooth muscle cells in Hirschsprung's disease into enteric neuron-like cells using small molecule compounds.2026Journal of pediatric surgery
  2. circANKRD12/circTIMMDC1 synergistically regulates enteric neural crest cell migration via miR-181b-5p-PROX1-NOTCH1 axis in Hirschsprung's disease.2026Pediatric research
  3. ERBB3 deficiency causes a multisystemic syndrome in human patient and zebrafish.2024Clinical genetics
  4. Up-Regulation of microRNA-424 Causes an Imbalance in AKT Phosphorylation and Impairs Enteric Neural Crest Cell Migration in Hirschsprung Disease.2023International journal of molecular sciences
  5. Histopathology of Ganglion Cells in the Proximal Resected Bowel Correlates With the Clinical Outcome in Hirschsprung Disease: A Pilot Study.2023The Journal of surgical research
  6. Common variation of the NSD1 gene is associated with susceptibility to Hirschsprung's disease in Chinese Han population.2021Pediatric research
Earlier papers (2016–2020)6
  1. Genetic variants in RET, ARHGEF3 and CTNNAL1, and relevant interaction networks, contribute to the risk of Hirschsprung disease.2020Aging
  2. MicroRNA-4516-mediated regulation of MAPK10 relies on 3' UTR cis-acting variants and contributes to the altered risk of Hirschsprung disease.2020Journal of medical genetics
  3. Common variants of NRG1 and ITGB4 confer risk of Hirschsprung disease in Han Chinese population.2020Journal of pediatric surgery
  4. Common genetic variants in GAL, GAP43 and NRSN1 and interaction networks confer susceptibility to Hirschsprung disease.2018Journal of cellular and molecular medicine
  5. Pathologically assessed grade of Hirschsprung-associated enterocolitis in resected colon in children with Hirschsprung's disease predicts postoperative bowel function.2017Journal of pediatric surgery
  6. Contribution of Common Variants in GABRG2, RELN and NRG3 and Interaction Networks to the Risk of Hirschsprung Disease.2016Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 4 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 7.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 002025

7 hospitals in Shanghai for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led4
  1. The novel application of syringe needle in recessive dystrophic epidermolysis bullosa syndactyly release surgery.2024Journal of the American Academy of Dermatology
  2. Genotype and phenotype correlations in 441 patients with epidermolysis bullosa from China.2023Journal of the European Academy of Dermatology and Venereology : JEADV
  3. The clinical efficacy and safety of anti-IgE therapy in recessive dystrophic epidermolysis bullosa.2022Clinical genetics
  4. Complex genetic models in dystrophic epidermolysis bullosa families with marked intra-familial phenotypic heterogeneity.2022Journal of the European Academy of Dermatology and Venereology : JEADV
Earlier papers (2016–2020)6
  1. Next-generation sequencing through multigene panel testing for the diagnosis of hereditary epidermolysis bullosa in Chinese population.2020Clinical genetics
  2. Gentamicin induces COL17A1 nonsense mutation readthrough in junctional epidermolysis bullosa.2020The Journal of dermatology
  3. Ankyloblepharon-ectodermal dysplasia-clefting syndrome misdiagnosed as epidermolysis bullosa and congenital ichthyosiform erythroderma: Case report and review of published work.2019The Journal of dermatology
  4. Updated review of genetic reticulate pigmentary disorders.2017The British journal of dermatology
  5. Gene diagnosis and prenatal genetic diagnosis of a case of dystrophic epidermolysis bullosa family caused by gonadosomatic mosaicism for the COL7A1 mutation p.Gly2043Arg in the pregnant mother.2016Journal of the European Academy of Dermatology and Venereology : JEADV
  6. A novel mutation in the COL7A1 gene results in a unique phenotype of epidermolysis bullosa pruriginosa.2016Journal of the European Academy of Dermatology and Venereology : JEADV

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

上海交通大学医学院附属新华医院

Xinhua Hospital

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Xin Hua Hospital; XinHua Hospital Affiliated to Shanghai Jiaotong University; Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College; Xinhua Hospital Affiliated to Shanghai Jiao Tong University; Xinhua Hospital affiliated with Shanghai Jiao Tong University; Xinhua Hospital of Zhejiang Province; Xinhua Hospital Chongming Branch; Dalian University Affiliated Xinhua Hospital

Suggest a correctionDownload the data